- Home
- FLYE vs COYA Comparison
FLYE vs COYA Comparison
Compare FLYE & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYE
- COYA
- Stock Information
- Founded
- FLYE 2018
- COYA 2020
- Country
- FLYE United States
- COYA United States
- Employees
- FLYE N/A
- COYA N/A
- Industry
- FLYE Aerospace
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- FLYE Industrials
- COYA Health Care
- Exchange
- FLYE Nasdaq
- COYA Nasdaq
- Market Cap
- FLYE 91.6M
- COYA 107.0M
- IPO Year
- FLYE 2024
- COYA 2022
- Fundamental
- Price
- FLYE $0.70
- COYA $6.51
- Analyst Decision
- FLYE
- COYA Strong Buy
- Analyst Count
- FLYE 0
- COYA 4
- Target Price
- FLYE N/A
- COYA $16.50
- AVG Volume (30 Days)
- FLYE 5.6M
- COYA 67.9K
- Earning Date
- FLYE 08-19-2025
- COYA 08-12-2025
- Dividend Yield
- FLYE N/A
- COYA N/A
- EPS Growth
- FLYE N/A
- COYA N/A
- EPS
- FLYE N/A
- COYA N/A
- Revenue
- FLYE $22,881,935.00
- COYA $423,452.00
- Revenue This Year
- FLYE N/A
- COYA N/A
- Revenue Next Year
- FLYE N/A
- COYA N/A
- P/E Ratio
- FLYE N/A
- COYA N/A
- Revenue Growth
- FLYE N/A
- COYA N/A
- 52 Week Low
- FLYE $0.51
- COYA $4.65
- 52 Week High
- FLYE $8.30
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- FLYE 24.77
- COYA 53.70
- Support Level
- FLYE $0.51
- COYA $6.41
- Resistance Level
- FLYE $0.84
- COYA $6.88
- Average True Range (ATR)
- FLYE 0.76
- COYA 0.45
- MACD
- FLYE -0.24
- COYA 0.03
- Stochastic Oscillator
- FLYE 2.24
- COYA 53.53
About FLYE Fly-E Group Inc. Common Stock
Fly-E Group Inc is an electric vehicle company that is principally engaged in designing, installing and selling smart electric motorcycles, electric bikes, electric scooters and related accessories under the brand Fly E-Bike. It also provides connectivity solutions and value-added services to their customers.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.